This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Rare Disease Innovation & Partnership Summit
March 21-23, 2023
Delivered as a Hybrid EventPhiladelphia Marriott Downtown

Joe Grieco
VP, Clinical Development at Tris Pharmaceuticals


Dr. Joseph Grieco joined Tris Pharma as Vice President of Clinical Development He leads clinical development and pharmacovigilance, informs asset development, and oversees the operational execution of clinical trials. Joe has an extensive background in clinical development programs in multiple therapeutic areas with a focus on severe rare congenital disorders including lysosomal storage disease, genetically based cognitive disorders, seizure and neo-natal conditions as well as severe ophthalmological conditions. Prior to his current role at Tris, Joe held roles of increasing responsibility in both biotech and academia. His early work began as an academic neuroscientist studying the molecular mechanisms of learning and memory with a focus on rare congenital disorders, specifically Angelman and Fragile X syndrome. Most notably during this tenure he identified the first candidate medicine for the treatment of Angelman syndrome which led to the first ever clinical trial in this population with a severe unmet need. Dr. Grieco holds a Ph.D. in Neuroscience and a M.S. in Medical Science from the University of South Florida, Tampa, Florida.

Agenda Sessions

  • Increasing Innovation in Clinical Trial Design